Table and Figure Legends
Table 1: Clinical baseline characteristics
Figure 1: The use of ezetimibe and PCSK9 inhibitor at baseline and during follow up
Figure 2: Changes in LDL-C with follow up
Figure 3: Proportion of patients achieving recommended LDL-C level < 2 mmol/L
Figure 4: Reasons for not following the recommended therapy